On examination, Mr L was a chronically ill-appearing man whose breathing was aided by nasal oxygen and who sat on a bedside "neuro" chair. He had a fourth cranial nerve palsy and disconjugate gaze, facial droop, hoarse voice, absent gag reflex, and coarse breath sounds. Chest x-ray showed multiple pulmonary nodules and a new patchy left lower-lobe infiltrate.
The medical house staff called a palliative care specialist, Dr A, who noted that the patient was receiving a dose of intrathecal liposomal cytarabine during his initial visit. Dr A discussed the patient with Dr O, who now estimated that the patient had "only a month to live." Dr A estimated a prognosis that could be as short as 2 weeks.
The palliative care team initially conferred with the patient's son and sister, outlined the likely prognosis, advised them to proceed with hospice enrollment, and outlined the requirement for a do-not-attempt resuscitation and do not intubate order for this hospice. After this meeting, all acknowledged that this was the end of beneficial palliative chemotherapy, which his oncologist was now no longer recommending. The family accepted these plans. Dr A then met Mr L and his wife, who agreed to these recommendations, and he met with the executor of the patient's estate whom he urged to immediately complete a durable power of attorney for legal and financial transactions. Later, Dr A met with Mrs L and 2 sons to answer their questions (eg, likely time course, signs of impending death, eating for pleasure rather than nutrition, how to inform relatives at a distance), then talked with the hospice nurse to begin hospice enrollment. Finally, at Mrs L's request, Dr A spoke with the patient's mother and brother in England, who were displeased with the plan for hospice enrollment.
Mr L was transferred to his home with hospice care, where he remained alert and interactive for several days. On the sixth day at home, Mr L died peacefully with his wife and his children at his side and with his favorite music playing, some 14 months after the initial diagnosis. His mother and brother flew in from abroad but arrived only after Mr L had died.
Mrs L, Dr A, and Dr O were interviewed by a Perspectives editor in August and September 2006, 2 months after Mr L's death. The appropriate role of chemotherapy near the end of life is a complex issue. 1 As chemotherapy is increasingly available, and better tolerated, its use at life's end involves sophisticated oncological assessment, a focus on the patient's goals of care, and a balancing of perspectives of the patient and treating oncologist. Ultimately, it may involve judgments about the use or restraint of use of costly resources despite little chance of benefit. 2 In some respects, Mr L's care proceeded appropriately from a cancer diagnosis to hospice care. But were there missed opportunities to improve Mr L's care? How can clinicians help patients and families determine when further chemotherapy is no longer beneficial and when they have had enough? Using the case of Mr L as an example, we discuss how clinicians can help patients identify the goals of therapy, the ways that oncology and palliative care clinicians can work together, and strategies to improve communication when chemotherapy is being considered at the end of life.
PERSPECTIVES

DR O (THE ONCOLOGIST): We discussed with Mr L and his wife that this [leptomeningeal carcinomatosis] was a very ominous turn of events and that without intervention, his prognosis was clearly going to be weeks to a couple of months or so. His choices were to just focus on his comfort or to try to see if
From the viewpoint of oncologist Dr O, Mr L presented with stage IV lung cancer, with brain and bone metastases. His cancer initially responded to brain and spinal radiation and first-line chemotherapy but then progressed. It stabilized for several months on a second-line agent, but a thirdline agent did not halt its growth. He died of leptomeningeal metastases that progressed despite 2 types of intrathecal chemotherapy. He lived 14 months, fairly typical for nonsmall cell lung cancer, but spent only 6 days in home hospice before death. At the time of the first visit by Dr A, the palliative care physician, Mr L was still a full code and had not made any financial transition plans, although he did have a designated power of attorney for health care, which may be more important, 3 and Dr A believed that the family and patient were unprepared for the nearness of death. Dr A bore the brunt of some family anger when recommending hospice. He responded by stating that oncologists "need to be trained to involve palliative care folks earlier." However, the oncologist had brought up hospice, and the patient initially declined it, only accepting palliative care involvement when death was imminent. The admitting house staff and palliative care consultant had a sense that this patient with brain metastases was not always making informed choices and had lost opportunities to do other important things with his remaining time while pursuing further chemotherapies and clinical trials. They had concerns about providing care (such as the final dose of intrathecal chemotherapy) that really could not help the patient.
Identifying the Appropriate Goals of Chemotherapy
Reasons for Late-Stage Chemotherapy. Patients may find it hard to get or accept truthful information about the benefits and harms of palliative chemotherapy. In the largest study of 95 consecutive patients receiving palliative chemotherapy, prognosis was discussed by only 39% of medical oncologists. 4 In a longitudinal study of hospitalized patients for whom death was believed imminent, families reported that the attending physician never discussed the possibility of death 62% of the time and no one on the medical team discussed the possibility of death with cancer patients in 39% of cases. 5 In other studies, at least one-third of patients and families reported they did not believe the information given them that treatment was not curative despite receiving such information. 6, 7 Another study showed that physicians may "collude" in this hopefulness by giving such a wide range of outcomes that people choose the most favorable. 8 It is critical to understand that people looking death in the eye have a different perspective. Studies from the United States, England, Canada, Japan, Norway, and Italy consistently show that patients with cancer generally were willing to undergo aggressive treatment with major adverse effects for very small chance of benefit, different from what their well physicians or nurses would choose. 9 Some patients with previously treated non-small cell lung cancer would accept chemotherapy for a survival benefit as short as 1 week, while others would not, even for a benefit of 2 years (the actual expected benefit was~3 months). 10 Highly educated and motivated patients enrolled in phase 1 studies at the National Cancer Institute said that they would be willing to take an experimental drug-with a 10% mortality rate-for an unknown small chance of benefit.
11 BOX 1 lists some of the difficulties in giving and receiving information about prognosis in advanced cancer.
Multiple studies document that palliative chemotherapy is increasingly given near death. More than 20% of patients receiving Medicare who had metastatic cancer started a new chemotherapy treatment regimen in the 2 weeks before death. 29 In Italy, 23% of patients with incurable cancer received chemotherapy within 30 days of death. 2 In a US community practice, chemotherapy for patients with lung cancer was given within 30 days of death for 43% and 14 days for 20% of patients. 30 In 2008, a medical director of a large insurance company reported that 16% of its cancer patients receive chemotherapy within 14 days of death. Patients are unlikely to benefit from chemotherapy when they have already been failed by the standard regimens, have poor performance status, and otherwise have a poor prognosis. The largest study of matched patients who received hospice and no chemotherapy vs those who did not receive hospice care but had chemotherapy showed that survival was significantly longer for hospice patients with lung cancer and pancreatic cancer, marginally longer for colon cancer, but no different with breast or prostate cancer. The authors concluded that this was consistent with chemotherapy not prolonging and possibly shortening life for those eligible for hospice. 31 Furthermore, chemotherapy produces adverse effects, precipitates hospitalization and emergency department visits, precludes entry into most hospices, and may require additional supportive care with erythropoietinlike drugs and colony-stimulating factors that are expensive and contribute little to the patient's overall quality of life. For these reasons, the factors that go into patients' decisions to undergo chemotherapy near the end of life bear examination.
Is Distinguishing Curative From Palliative Chemotherapy Important? Chemotherapy for metastatic solid tumors such as lung, breast, colon, or prostate cancer rarely if ever cures patients. The indication for such chemotherapy is to improve disease-free or overall survival, relieve symptoms, and improve quality of life. Palliative chemotherapy accounts for most of the work of everyday oncology given the rarity of curable disease. The American Society of Clinical Oncology could not decide on a minimal benefit for which chemotherapy was indicated, only that some benefit must be demonstrable. 32 Consensus panels that include cancer advocates make little distinction between curative treatment and palliative treatment that could extend life, 33 since 6 months' added survival could be as important as an increased rate of cure.
The increasing effectiveness and lessened toxicity of palliative chemotherapy is well supported by randomized trial data. First-line chemotherapy for patients with non-small cell lung cancer improves survival by 2 to 3 months, relieves symptoms, and improves quality of life compared with best supportive care. 34 Second-line treatment of patients with non-small cell lung cancer with docetaxel vs best supportive care is associated with significantly longer survival (7.0 vs 4.6 months, or 10 weeks, and a difference in 1-year survival, 29% vs 19%) 35 ; and improvements in pain and less deterioration in quality of life. 36 Even third-line treatment may improve survival or symptoms, especially with novel, relatively nontoxic oral agents such as erlotinib, which, in 
Small Cell Lung Cancer
Thirty-five patients reported learning more about their prognosis from other patients in the waiting room than from their health care professionals. Physicians did not always want to pronounce a "death sentence," and patients did not always want to hear it.
12
High-Dose Chemotherapy (With Stem Cell Transplant) Physicians prescribing high-dose chemotherapy overestimated survival, especially for patients with poor prognosis who might most need to balance toxicity with outcomes. 13 The optimistic patients had no better survival than those who were more realistic.
14
Terminally Ill With Cancer
Even if patients requested survival estimates, physicians said that they provided them only 37% of the time. Physicians reportedthattheywouldprovidenoestimate,consciousoverestimates, or conscious underestimates 63% of the time.
15
Solid Tumors
In Belgium, only 39% of oncologists reported ever reviewing prognosis with patients. Most of the interview was spent on active treatment, not alternatives. 4 Nearly all patients could name their diagnosis, but only 23% knew their stage, which is critical to appropriate goal setting. 16 Oncologists consistently overestimated prognosis by at least 30%. 17 In our own study, physicians' estimate of survival could be divided by 3.5 for actual survival.
18
Patients Don't Believe Information About Benefits and Risks of Treatment
Metastatic Lung Cancer
One-third of patients thought they were receiving therapy with curative intent despite being told prognosis and goals of care.
6
Head and Neck Cancer Thirty-five percent of patients believed their palliative radiation was supposed to be curative.
7
Phase 1: Overoptimistic If told that a treatment helps 20% of people like them, patients reported a 44% chance of it helping them personally.
19
Patients Change Their Mind About Communication
Metastatic Breast Cancer
Between first and second lines of chemotherapy, 59% of 729 patients with advanced cancer changed their preference about involvement in decision making; 37% wanted a less active role, and 22% wanted a more active role. 20 Thirty-eight percent of women took an active role in decision making for first-line chemotherapy, and 43% for second-line chemotherapy. The reasons to take chemotherapy shifted from the possibility of controlling the tumor (50% for first chemotherapy, 38% for second) to providing hope (19% for first-line chemotherapy, 43% for second line); the proportion expecting to be cured fell from 10% to 0% with second-line chemotherapy.
21
Patients Have Different Perspectives Than Their Well Health Care Professionals
Solid Tumors England
Patients would have toxic treatment for a 1% chance of cure, 10% chance of symptom relief, or chance to prolong life 12 months. Their physicians and nurses would require a 50% chance of cure, 75% chance of symptom relief, and 24 to 60 months added survival. 22 Patients accepted a lower chance of benefit from chemotherapy than their physicians or nurses, even when treatment involved great toxicity. 
Lung Cancer Norway
Patients younger than 40 years would accept the toxic treatment with only a small benefit: chance of cure (median, 7%), life prolongation (3 months), and symptom relief (8%).
25
Italy
Patients would be willing to undergo chemotherapy for small benefit, even if the physician presents the results pessimistically.
26
United States
Patients who had undergone chemotherapy for lung cancer would take it again if it added survival of 4.5 months with mild toxicity or 9 months with severe toxicity. When given the choice between supportive care and chemotherapy, 22% chose chemotherapy for a survival benefit of 3 months, which was the actual expected benefit. Sixty-eight percent would choose chemotherapy if it substantially reduced symptoms without prolonging life. Only a quarter remembered hearing any options about treatment that did not involve chemotherapy, such as palliative care.
4
Japan
If their lives would be prolonged by 3 months, 19% would choose to receive intensive treatment, and 21% would choose less intensive treatment. With a 70% chance of symptom relief, 73% of patients were willing to choose intensive chemotherapy.
27
Palliative Chemotherapy, Belgium Patients'choiceforchemotherapyorpalliativecarewasmoststrongly predicted by their preconsultation treatment preference.
1 study, improved survival compared with best supportive care from 4.7 to 6.7 months with improved results for pain, dyspnea, and physical functioning. 37 Palliative chemotherapy has also increased survival and quality of life in metastatic colorectal 38 and prostate cancer 39 (TABLE 1) . Mr L benefited from receiving 3 separate types of palliative nonsmall cell lung cancer chemotherapy: gemcitabine and carboplatin, oral erlotinib, and pemetrexed. Although he never had dramatic responses to treatment, his disease stabilized for months while he received the first 2 treatments, and his central nervous system disease was stable for weeks because of intrathecal methotrexate.
How Can Clinicians Help Patients With Decision Making? Mr L's palliative care specialist noted that because patients are vulnerable to fastening on slim hopes, oncologists must improve their skills in helping patients think clearly about the appropriateness of chemotherapy. 44, 45 To help their patients make wise decisions, oncologists can start with a prompt list of questions, proven to enhance communication 46-48 and similar to one in use in several oncology practices, 49 ,50 including ours
. This can be provided to the patient in the waiting room for discussion with his or her physician.
Another important communication is a straightforward discussion of the quality and quantity of life with or without chemotherapy. In most cases, there will not be a randomized trial of best supportive care vs best supportive care plus chemotherapy, but at least the important discussion points can be raised. There must be some definable benefit before chemotherapy can be recommended. Studies consistently document that patients want and use such information. Of 126 terminally ill patients, 98% said they wanted their oncologists to be realistic 51 and patients want oncologists to be truthful and compassionate and to continue caring for them during their illness. 52 A comprehensive review found that randomized trials of decision aids in oncology yielded increased patient knowledge and more involvement in decision making, 53 and a decision aid for adjuvant therapy of breast cancer (http://www.adjuvantonline.org) improved medical decision making and helped low-risk patients avoid unnecessary chemotherapy.
54,55 A preliminary study showed that directly giving patients information about prognosis and treatment to share with their oncologist is desired and helpful. 56 We use decision aids in our own practice that address prognosis with and without chemotherapy in a question-and-answer format, using simple terms (ie, "10 in 100 people" instead of "10%") and figures.
What In the difficult situation faced by Dr O and Mr L, when the oncologist thinks further chemotherapy is not indicated, a number of strategies may be tried: holding family conferences to identify the decision makers in the family and getting the same information to all involved; informing people of and giving them access to the actual medical research studies and results; or writing the options down in concrete terms. 57 Much of the time, patients and families may simply need more time to adjust to a difficult situation. Sometimes, they just have a different perspective that must be valued as much as the health care professional' s. Making the transition to palliative care or hospice is difficult for both patients and oncologists. There are usually some treatment options, even for relapsed disease. The available lung cancer treatment data suggest that each 3.3% of response rate leads to better survival of 1 week and increases survival at 1 year by 1.6%, which might be important to some patients. 58 The National Comprehensive Cancer Center Network guidelines recommend that after 2 chemotherapy regimens have failed to benefit the patient or if the patient's performance status declines to 3 or more, such that chemotherapy will not be tolerated, a switch to palliative or hospice care be made (http://www.nccn.org /professionals/physician_gls/default.asp). The American Society of Clinical Oncology and other major professional societies have long recommended hospice as the best available care for dying patients.
TRANSITIONING TO PALLIATIVE
59
In our experience, many families and patients who choose, like Mr. L, to enroll in hospice wish they had done so sooner. The median length of stay on hospice has declined from 29 days in 1995 to 26 days in 2005, with one-third enrolling in the last week of life and 10% on the last day of life (http: //www.nphco.org). Hospice care may help the family as well as the patient. One study showed that hospice care was associated with a 0.5% lower absolute risk of death for the Medicare-age surviving spouse.
60 Families' perception of late referral is associated with lower satisfaction with hospice care overall. 61 In the most recent and largest study, among those with hospice stays of less than 30 days, 16% of families said they were referred too late. 62 Of note, the perception of being referred too late, but not the actual length of stay, was associated with more unmet needs, lower satisfaction, and more concerns. One study found that patients would have liked palliative care consultation earlier in their course. 63 It is unknown whether this view of "too-late" referrals to palliative care and hospice will change with the new relatively nontoxic chemotherapy treatments. Don't assume that people will or won't want to know their diagnosis.
Although cultures vary, most patients want to know their prognosis and options. They may underestimate their odds, too, and forgo useful chemotherapy. Define "response" and "cure."
Patients can mistake a 20% chance of response with a 20% chance of cure.
Write down a list of benefits of and adverse effects from chemotherapy. Don't assume that patients will know their odds of being helped.
There must be some definable benefit before chemotherapy is justified.
Ask patients their goals. Two months may be critical to some people, unimportant to others.
Begin a discussion about what to do if or when the cancer is resistant to chemotherapy. This is a good place to say, "We hope to control the disease, but at some point it may grow so that it will end your life. We need to prepare for that, too." Treatment Say, "The cancer is shrinking, but is still there." Don't say, "The cancer is responding." If you say this, estimate that it will likely last for however many months.
Important to emphasize what is likely to happen, so that people can make plans.
Be hopeful if there is reason to hope about the cancer.
Most people can be hopeful about something, even if their cancer is growing. Begin a discussion about do-not-attempt-resuscitation orders.
This is a good place to say, "The cancer is growing, and may end your life. There are some important issues to discuss. Tell me how much you want to know."
End of Life or Cancer Progression
Bring up hospice when there are still some oncology options, not at the end of life.
Don't ask hospice to just manage the acute deaths at home.
Make hospice an option that is part of usual medical care for someone with cancer. Ask for your own hospice length of stay and the number of your patients who die within 7 days of enrollment.
Make this a performance improvement goal for the practice to meet or exceed the national length of stay in hospice. Tell people you will not abandon them if they enroll in hospice.
Some physicians make appointments for every 2 weeks even for hospice patients. If they are too sick to attend, it is a good reminder to check in by telephone or visit.
CHEMOTHERAPY AT THE END OF LIFE
©2008 American Medical Association. All rights reserved. Another explanation is that such discussions are simply too difficult and painful. Even clinicians who are well trained and skilled at giving bad news can find it burdensome and emotionally difficult. Prior surveys documented "serious shortcomings in the training and current practices of oncologists" of palliative care and that only 25% of oncologists found end-of-life care highly satisfying. 69 Given the incurability of some cancers, such as with Mr L, there is a need for these conversations and consideration of hospice care. At the very least, finding out how much a patient wants to know and then providing that information should be addressed by all clinicians. Clinicians often struggle with initiating discussions about shifting treatment goals and in particular transitioning to palliative care. Patients may respond with denial, anger, or sadness. These are all normal responses to the associated loss of control, a fear of the immediate future, or an underlying fear of death. For the most part, patients and families will have their own unique timetable and method for processing this information. 7 Clinicians should generally respond with patience, emphasizing support (nonabandonment) and assurance of aggressive symptom management 71 (Table 2) . Not surprisingly, physicians may respond to their patients, particularly those with whom they share a longterm relationship, with powerful emotions of their own.
72
These can include a personal and professional sense of failure and frustration, guilt, powerlessness against the illness, grief, a need to rescue the patient, or a desire to separate from and avoid patients to escape these feelings.
73
Clinicians' feelings of medical ineffectiveness can lead to failure to identify patient-specific and family-specific values influencing decisions, which may lead to a lack of clarity about care goals. Avoidance of the discussion altogether can lead to mistrust of the health care system and medical profession, inappropriate use of life-sustaining medical technologies, increased medical complications, and long hospital stays. 74 Recognizing, accepting, and reflecting on the normalcy of such feelings allows the professional to make a conscious choice about how to proceed in the relationship with the patient. Finding a trusted colleague in whom to confide can be part of a plan to prevent isolation, improve objectivity, and avoid burnout. No data are available that show hope can be taken from patients, as was once thought, or that patients are harmed by carefully provided information. 76, 77 As the Education Physicians End of Life Care for Oncologists (EPEC-O) curriculum 78 states, "Information carefully shared is a gift to the patient and the family who want it and minimizes the risk that patients will distrust the cancer care team." In pediatric oncology, full prognostic disclosure supported hope, even when the prognosis was poor. Evidence, albeit far from conclusive, suggests that "concurrent" palliative or hospice care alongside routine oncology care improves health outcomes (TABLE 3). Project Safe Conduct was started to integrate hospice care into lung cancer care at the Ireland Cancer Center. Before the study, 13% of patients with advanced lung cancer were referred to hospice; afterward, 80% of such patients enrolled in hospices and the average length of stay in hospice increased from 10 days to 44 days. 81 The one randomized trial of concurrent hospice care plus usual oncology care vs usual oncology care alone has been published only in abstract form. 80 The group with concurrent care lived slightly longer (not statistically significant), had quality of life preserved longer, used less chemotherapy, and transitioned to hospice enrollment sooner. The clinical care differences were modestly in favor of the concurrent-care approach, but the hospice cost was substantial and much higher than the cost of hospitalizations avoided (oral communication, John Finn, MD, Ascension Health Systems, Detroit, Michigan, October 2004). Meyers and colleagues 84 enrolled patients in a phase 1 and 2 cancer treatment study and into a simultaneous care program that emphasized symptom management and transition to hospice. The uptake of the program was excellent. Patients received as many cycles of chemotherapy as without simultaneous care and were referred to hospice more frequently and earlier. A study at the Dana Farber Cancer Institute showed that cancer patients will use a free palliative care service alongside their usual oncology care, but health outcomes are not yet available. 1 The one large randomized controlled trial of usual care plus palliative care consultation, in which 27% to 34% of patients had cancer, showed no difference in symptoms or survival but did show a $4855-per-patient cost savings. 85 Proof of symptom control or survival improvement at a cost society can afford will require rigorous testing, preferably in randomized clinical trials.
One of the largest barriers to hospice in the United States is the way it is defined in the Medicare Hospice Benefit. Patients must have a life expectancy of 6 months or less and must forego curative treatment. Funding for chemotherapy and radiation is limited; thus, being enrolled in hospice can significantly limit very useful palliative treatment. Several hospice programs have begun to respond to these eligibility barriers and are providing a broader range of services. 45 Some have changed to palliative care programs under home health care services, integrating palliative che-CHEMOTHERAPY AT THE END OF LIFE motherapy and radiation and related treatments (paid for by the patient's insurance or Medicare drug benefit) with elements of traditional hospice care. Passik and colleagues 86 at Hospice of the Bluegrass showed that patients who transition from acute care to palliative care then to the hospice benefit, compared with those who transition directly from acute care to the hospice benefit, may prove to be both financial and care burdens to the hospice. As noted above, a randomized trial showed palliative care consultation alongside usual medical care saved the insurer $4855 per patient with no decrement in survival or symptoms. 85 Several larger insurance-sponsored trials are ongoing. Patients on clinical trials have as good an understanding of the risks and benefits as we can give them-after all, they have read and signed informed consent documents-but this understanding is far from perfect. Despite written information, many will still overestimate their own particular chance of success. 19 Mrs L expressed, as do many patients and families, that they hoped Mr L would survive long enough to receive a new treatment, or even a cure. And as we noted above, informed phase 1 patients are willing to undergo new treatments with a 10% mortality risk for an unknown but low chance of benefit.
INTEGRATING OTHER CANCER CARE ISSUES INTO DECISION MAKING AT THE END OF LIFE
Reimbursement and Economic Issues: Why Oncology is Different
Most palliative care is relatively inexpensive. However, palliative chemotherapy regimens have a huge price tag, at a cost of up to $100 000 a year per patient, and even insured patients can be burdened by a 20% co-payment requirement. The cost of palliative chemotherapy for colorectal cancer could easily be $50 000 a year, not counting supportive care drugs or imaging. 87 Patients with cancer account for about 40% of all Medicare drug costs, totaling an estimated $5.3 billion in 2006, with $1.5 billion for erythropoietinlike drugs alone.
88 Some drugs (oxaliplatin for metastatic colon cancer 89 and docetaxol for metastatic prostate cancer 42 ) have acceptable cost-effectiveness ratios in which Only shows some improvement in symptoms but no difference in survival at increased cost due to the high cost of interdisciplinary hospice services when used for palliative care (unpublished). For patients at a comprehensive cancer center referred to palliative care, severe distress on admission and severe symptoms of distress significantly improved after palliative care consultation. Mean daily charges in the patient care information system were 38% lower than the mean daily charges for the rest of the hospital.
First published demonstration of better symptom control and lower costs for patients at a tertiary comprehensive cancer center; not really concurrent care. Supportive care may enhance coordination of care and facilitate patients' explicit transition from curative intent to palliative intent; a comparative randomized trial evaluating supportive care has yet to be completed.
Temel et al,
treated patients gain several weeks or months of life, at a cost less than $100 000 per additional year of life saved, but for Medicare, these are new costs to pay. For Mr L, his last dose of intrathecal cytarabine given 6 days before his death would cost $3400 at our institution. The manner in which oncologists are reimbursed may play a role in chemotherapy use. Over the past 10 years, oncologists have become some of the highest paid medical specialists. 90 Some of oncologists' practice income comes from administering and selling chemotherapeutic agents and supportive care drugs (eg, bisphosphonates, erythropoietinlike drugs and colony stimulating factors). As is the case in other medical specialties, oncologists are reimbursed more for their specialized treatment of chemotherapy than for lengthy discussions about prognosis and palliative care options. 91 This potential for conflict of interest has been the subject of controversy. The only published study was conducted before Medicare chemotherapy reimbursement was reduced in 2003 and found that reimbursement did not affect the decision to give palliative chemotherapy but that oncologists tended to choose chemotherapy that gave the highest profit to the practice. 92 Although hospice care and inpatient palliative care 93 may save money during the last month of life, total disease costs are unchanged or increased, 94 so hospices cannot save enough money to allow more chemotherapy. It is critical to improve reimbursement incentives. For example, in 1 study, more than 25% of oncologists reported insufficient reimbursement for time spent in discussion with patients and families as "the most troublesome" reimbursement barrier to providing better end-of-life-care.
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If societal resources become limited, and maximizing health benefit becomes more difficult, there are only a few ways to reduce the cost of oncology care:
• Reduce the services provided (eg, "stopping rules," 95 in which no more than 3 lines of chemotherapy would be given for refractory metastatic breast cancer or no erythropoietinlike drug treatment for anemia would be given unless the hemoglobin is Ͻ10 g/dL):
• Reduce requested services by increasing patient copayments.
• Reduce the amount that Medicare or insurers pay for chemotherapy and supportive care drugs, health care professional services, or hospitalizations.
• Prevent or delay new drugs from entering the market, or delay reimbursement for them.
• Reduce the payment to oncologists for administering chemotherapy and supportive care drugs, perhaps influencing the type of chemotherapy administered.
Ultimately, unless resources are unlimited, patients and families (or society at large) may be asked to balance individual patient needs against those of society.
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CONCLUSION
Given understandable patient, family, clinician, and societal goals and concerns, how can all individuals be educated and informed as to the appropriate use of chemotherapy and the value of palliative care and hospice? First, as suggested by hospice experts and oncologists, 12 someone other than the oncologist might give information about the hospice option and provide specific prognosis and palliative treatment information. Second, palliative care specialists should be aware of the difficult decision making that cancer patients face near death, and how different their perspective is about benefit and toxicity. 9 Decision aids may be used. Finally, regarding palliative care options, completion of studies integrating hospice and palliative care into usual oncology care will permit evidence-based decision making.
The conundrum for today's oncologist is that moving on to third-or fourth-line chemotherapy may be easier than discussing hospice care, the patient and family may be less upset, and they may prefer to not discuss the issue with the oncologist. 68 Adverse effects of chemotherapy may be minimal, discussions take more time, and chemotherapy intervention is better compensated than are discussions. However, without a clear goals-of-care discussion, patients like Mr L and their families may be unprepared for what the final few months, weeks, or even days may bring. Through honest and respectful communication about the last stages of cancer, physicians can give patients a genuine choice about how to spend their last phase of life. (1) O ver the last century, developments in new medical treatments have led to an exponential increase in longevity, but, as a consequence, patients may be left with chronic illness associated with long-term severe functional and cognitive disability. Patients and their families are often forced to make a difficult and complex choice between death and long-term debility, neither of which is an acceptable outcome. Traditional models of medical decision making, however, do not fully address how clinicians should best assist with these decisions. Herein, we present a new paradigm that demonstrates how the role of the physician changes over time in response to the curved relationship between the predictability of a patient's outcome and the chance of returning to an acceptable quality of life. To translate this model into clinical practice, we propose a 5-step model for physicians with which they can (1) determine at which point the patient is on our model; (2) identify the cognitive factors and preferences for outcomes that affect the decision-making process of the patient and his or her family; (3) reflect on their own reaction to the decision at hand; (4) acknowledge how these factors can be addressed in conversation; and (5) guide the patient and his or her family in creating a plan of care. This model can help improve patient-physician communication and decision making so that complex and difficult decisions can be turned into ones that yield to medical expertise, good communication, and personal caring.
CHEMOTHERAPY AT THE END OF LIFE
Arch Over the last century, developments in public heath and new medical therapies have led to an exponential increase in lon-gevity. Treatments offered by modern medicine can now avert death, but patients are often left with longterm severe functional and cognitive disability. Patients and their families are forced to make difficult and complex choices between death or severe debility. In this article, we review why traditional models of medical decision making do not fully address these complex decisions and then present a new paradigm to assist with them.
EXISTING MODELS OF MEDICAL DECISION MAKING Paternalism
The model of paternalism guided medical decision making from the time of Hippocrates until the 1970s. In that paradigm, patients were allowed to be passive and therefore exempted from their responsibilities in making their own health care decisions, 1 as it was believed that their illnesses made them incompetent to make choices. 2 Clinicians were charged with making all decisions for the patient, 3 including establishing priorities for care. In a primarily male-dominated, nonpluralistic society, this model worked well, particularly because there were few treatment options available to patients. Also, most patients had long relationships with their physicians, and there was an overall culture of inherent trust in authority figures. As medical care evolved, numerous problems with the paternalism model came to light. Input about desires for quality of life was not sought, and cultural and religious factors relating to health care were ignored. The model began to fall out of favor in the 1970s, partly as a result of an increasing distrust in medical authority figures and the increasing number and complexity of medical decisions. 4 For all these reasons, the autonomy model was created.
Autonomy
Under the autonomy model, clinicians are responsible for informing patients and their families regarding the salient issues in their care and the available treatment options, but the ultimate decision is made by patients 5 and, after the landmark case of Karen Ann Quinlan in 1976, 6 by families. The difficulty with the autonomy model is that it presumes that physicians can translate their knowledge and experience in a manner that allows patients and families to grasp the implications and nuances of a particular decision. Patients are ill, families feel overwhelmed, and decisions therefore become difficult if not impossible. Short of handing patients or family members a textbook of medicine and infusing into them the physician's clinical experience, they cannot be expected to make truly informed choices. As these limitations became apparent in the 1990s, the shared decision-making model was created.
5,7,8
Shared Decision Making
In shared decision making, physicians work with patients and families to make health care decisions. 4, 5 This model assumes that clinicians and patients can evaluate the options together in a systematic way, consider the benefits and burdens of each treatment, and arrive at clear and logical decisions. 5 Although seemingly combining the benefits of both paternalism and autonomy, the shared decision-making model is rooted in the assumption that patients and families make decisions in a rational way based solely on the clinical evidence. While physicians often make decisions by applying the latest evidence-based medicine to clinical scenarios and then assessing the likelihood of potential outcomes, patients and their families do not proceed in this fashion. 9 The stress of illness, prior experiences with health care, and fears of future complications 10 may lead patients and families to make decisions that lead health care providers to label patients and families as "having unrealistic hopes," "being in denial," or "acting irrationally."
A NEW MODEL: TITRATING GUIDANCE
We propose a new model whereby the physician's role in decision making is matched to the patient's likelihood of recovery. Unlike previous models that describe a static role for physicians, this paradigm demonstrates how the physicians' role adapts over time in response to changes in patients' states of health. As shown in the Figure, there is a curved relationship between the predictability of a patient's outcome and the chance of returning to an acceptable quality of life. Our model is accompanied by a series of steps that can help clinicians translate theory into improving clinical care. Figure. Conceptual model of the relationship between the ability to accurately predict outcome and the diminishing chance of returning to an acceptable quality of life. As illness progresses, the role of the physician changes across the entire continuum, but for the sake of clarity only 3 points are shown. 
Left of the Curve
At the left of the curve, patients are healthy, so the outcome is easily predicted and there is a high probability of recovery. The role of physicians at this part of the curve is to provide information, as the choices are relatively straightforward, with low risks.
Top of the Curve
At the top of the curve, the outcome is difficult to predict and it is not possible to determine the patient's probability of recovery. Patients and families need the most assistance from clinicians at this point on the curve because the most complicated decisions lie here. Each question creates a seemingly endless series of subsequent additional choices and conundrums. One way to guide patients and families at this point is to acknowledge that there are numerous factors that influence decision making. For example, uncontrolled physical symptoms, 11 depression, 12,13 functional status, 12 anxiety, 14 lack of feeling in control about one's own health, 15, 16 and trust in physicians have all been shown to influence patients' desires to engage in decision making. The family and the caregivers are particularly important because they can also suffer from emotional and physical strain, [17] [18] [19] which may influence their decision making. Cultural, religious, and socioeconomic issues play a role and may even be in conflict.
In addition to these concerns, an understanding of the cognitive and psychological processes that influence decision making is key. One issue for patients and families at the peak of the curve is their concerns about future regret. 10 It has been postulated that the potential regret of having failed to "do everything" (ie, refusing treatments or interventions) is so great that patients will choose treatments even if they are presented as having a small likelihood of benefit. 20 After one path is chosen, the family may always wonder what would have happened had they chosen an alternate path, leading to a state of indecision. "Sunk costs" are another factor that clinicians must understand in communicating with patients and families. Adapted from economics, 21 this theory postulates that once patients have begun a certain treatment, they will continue with it (regardless of efficacy or future discomfort) to avoid the feeling that any resources (including time) used until this point were not wasted. 10 In addition to these psychological factors, physicians must consider patients' and families' preferences and values for acceptable outcomes. Decisions about interventions are ultimately a comparison of the benefits of a particular treatment weighed against its burdens. Acceptable outcomes vary based on the benefit-burden analysis of the individual patient and family members. The balancing of this equation may be influenced by past experiences with the health care system (either for themselves or others), and physicians may need to inquire about these experiences to better understand how they shape the decision-making process.
Physicians must also examine the role their own emotions play in the guidance they provide. Concern for future regret also can affect physicians. When counseling families about stopping treatments, clinicians may wonder if there is just "one more thing" that can be done, a feeling that can influence the way they counsel individuals as well as turn into an enduring sense of guilt after the patient dies. 22 Sunk costs may also affect physicians; clinicians may feel that terminating therapies invalidates their original rationale. In terms of personal values, it is important to remember that an acceptable outcome for the patient may differ dramatically from what clinicians would want for themselves. 23 Finally, physicians' reactions can have a concrete influence on the family. For example, unconscious emotions may alter the way that a physician frames a medical treatment or problem. Studies have shown that patients are more likely to choose treatments if the outcome is presented in terms of survival rather than mortality rates, even when the odds are the same. 9, 24 For all the reasons outlined above, decisions at the peak of the titrating guidance curve may be even more difficult for families and patients than they first appear. Suggested communication tools to be used at the top of the curve, including phrases to begin these conversations, are shown in Table 1 .
Right of the Curve
At the right of the curve, the outcome is easily predicted, but the chance of return to an acceptable quality of life is almost nil, because at this point the patients have advanced illness. There is little to no chance of recovery, and choices often relate to desire for symptom control, maximizing quality of life, and location and nature of death. Patients and families must deal with balancing treatment options with personal values and preferences, and the process of making these decisions is complex and distressing. Because there are ultimately few paths down which the treatment plan can proceed, the role of the physician changes from guiding decision making to reducing emotional and psychological stressors.
USING THE TITRATING GUIDANCE MODEL IN PRACTICE
As outlined in Table 2 , applying the guide to practice can be accomplished through a 5-step process:
(1) determine where the patient is on the curve; (2) identify the emotional and cognitive factors affecting patient/ family decision making (which may be articulated as values, preferences, and past health care experiences) and determine which factors need further exploration; (3) reflect on the physician's own reactions to the decision at hand, including personal preferences and values, acknowledging that they may differ from those of the patient; (4) determine how each of these factors can be addressed on the part of the patient/family as well as the physician; and (5) guide the patient/family in creating a plan of care.
Steps 1 through 4 are done by the physician as preparation for step 5, which occurs as a conversation with patients and their families. 
Left of the Curve
Returning to the case of Mr G, consider the clinical scenario when he was first diagnosed as having atrial fibrillation. At that point, his physician wanted to add warfarin to his medication regimen. First, Dr R thinks about the titrating guidance curve and determines that because Mr G is relatively healthy and because data about the benefits and burdens of anticoagulation are robust, this conversation occurs at the left portion of the curve. (While Mr G is based on an actual patient, Dr R is a hypothetical physician used to illustrate how the titrating guidance model can be applied in clinical practice; Dr R is not based on an actual clinician.) For step 2, she determines that it is unlikely that Mr G will have a strong emotional reaction to the conversation, but he may have some concern for future regret-wondering about what the outcome might be if he chooses the other path. She remembers that she needs to inquire about any previous experience Mr G might have had with others who have made decisions about anticoagulation and how such an experience might influence his own benefitburden analysis. In step 3, Dr R thinks about her own emotions. In her years of practice, she has had numerous patients who received anticoagulation, with only 1 case that she considers had a bad outcome. She acknowledges that her own personal bias would be to opt for anticoagulation if she were faced with this decision herself but also acknowledges that Mr G may have a bias toward not intervening. Fourth, Dr R considers how she will address the issue of concern for future regret, and she decides to tell Mr G about her single bad outcome. Finally, Dr R has a conversation with Mr G during which she outlines the need for the treatment, as well as its benefits and burdens. Ultimately, Mr G needs little guidance in making the decision, and Dr R respects and supports his choice regardless of whether it is in conflict with her recommendation or the personal preferences she might have for her own care.
Top of the Curve
Dr R uses a similar process in her approach to communication with Mr G's family members immediately after his stroke. First, she notes that the ultimate outcome cannot readily be predicted, and it is unclear what his future quality of life will be. The family members are being forced to make an extremely difficult decision: should they continue to support him in a physical state that he would have found intolerable, or allow him to die? Other questions arise, such as, "If they choose to start artificial hydration and nutrition [AHN], will Mr G be able to go home or will he need to be transferred to a long-term care facility?" "If they choose to not provide AHN, will they be able to live with their guilt?" "Can a trial of AHN be provided but stopped later if Mr G does not improve?" For all of these reasons, Dr R determines that the current decisions that need to be made place Mr G and his family at the top of the curve.
In step 2, Dr R examines the emotional and cognitive factors that are affecting the family's ability to make decisions. The family members have a range of reactions to Mr G's sudden illness, so their sadness, shock, and denial all play a role in their decision making. In terms of cognitive factors, sunk costs should also be considered; the idea of not providing all life-sustaining treatments may leave the family members wondering if they should have ever chosen to provide previous treatments (eg, thrombolytic agents) in the first place. Concern for future regret is particularly high; if the comfort path is chosen and the family foregoes AHN, they may always wonder what would have happened if they had chosen an alternate path. Preferences for quality of life also affect their decision. Is living in a state where he is alive but not able to communicate acceptable to Mr G? Some patients would find a life of dependency on others unacceptable, whereas others would consider it in line with their religious and moral values.
A strategy that is often used to assist patients and families in these complicated decisions involves a timelimited trial of AHN. In this scenario, Dr R decides that she understands the family well enough to propose that a gastric tube be placed for a prespecified length of time (eg, 1 month). This option will allow the family a better sense of the potential benefits and burdens of this treatment modality, and it will provide more time to see if his neurologic status improves. Of note, while withholding and withdrawing medical treatments are considered to be both legally and ethically equivalent, 25 patients and their families often may not see them as such. When the end of the allotted time frame arrives, Dr R plans another conversation about the outcomes observed by the family and the medical team.
In the third step, Dr R examines her own emotions. She has been Mr G's physician for many years, so she must acknowledge her own feelings of loss and grief. If the family chooses to forgo further life-sustaining treatments, then Dr R may be left wondering if there is just "one more thing" that could be done. This consideration of hers is a variation of concern for future regret, and it can turn into an enduring source of guilt for Dr R if Mr G dies. Dr R must also acknowledge the personal preferences that she might have if one of her family members were in the same situation as Mr G, and she must be sure that her own preferences do not color her conversation with the family.
Dr R must also consider how her framing of the medical options will affect the decision the family makes. It is unlikely that the family members will agree to stopping treatments if she asks, "Do you agree to withdraw care?" But they might agree to the concept of reframing the goals of care, 26 and Dr R could begin such a conversation by saying, "Let us focus now on assuring comfort and dignity in the time he has left instead of trying to prolong his life as long as we can." In both cases, she is asking about moving from a life-sustaining treatment plan to a comfort-oriented approach to care, but the framing of the second scenario is more consistent with the values expressed by Mr G's family.
In step 4, Dr R considers how she will handle these complex emotional and psychological issues when counseling the family. To address the degree to which the family is struggling with sunk costs, she will ask, "Are you concerned that stopping life-sustaining treatments now invalidates decisions that you have previously made?" To address concern for future regret, Dr R might say, "It is important to consider whether you will be comfortable with these choices when you look back on them 20 years from now." In terms of her own reactions, she could discuss the plan to stop AHN with Mr G's neurologist, or even ask for a second opinion, to lessen her own concerns for future regret.
In the final step, Dr R discusses the benefits and burdens of AHN with the family. For assistance with opening the conversation, Dr R chooses to use the informed recommendation tool described in Table 1 . She begins the conversation with, "Given what you've told me about your father and his desire for both independence and quality of life, I don't think it makes sense to put in a gastric tube. Tell me your reactions to my recommendation." Dr R then moves on to address the family's concerns about future regret and sunk costs. Ultimately, the family decides that a tube for AHN should not be placed.
Right of the Curve
Several weeks later, it becomes clear that Mr G cannot eat enough to sustain himself. At this point, Dr R reexamines where Mr G is on the curve. She knows that recovery is unlikely, and so the decision now is whether the family will care for him at home or admit him to an inpatient hospice. The choices are well defined, and regardless of what is selected, the ultimate outcome-death-is known. Dr R therefore determines that the current decision is on the rightmost portion of the curve.
Next, Dr R determines both the emotional and the cognitive factors that influence the family's decision making at this point. Sunk costs are not particularly applicable, and concern for future regret will come into play only if Mr G's family is not provided with the resources (in terms of both guidance and medications) to ensure that his final days are comfortable. The family members may have preferences based on past experiences with the care of other family members or on their own personal beliefs about where Mr G should die. Likewise, although Dr R may have a strong emotional reaction to Mr G's death, she realizes that because of the straightforward nature of the choices to be made, her emotions are unlikely to influence the way she guides the family (step 3). While she knows that if her father were in this situation she would want him to die at home, she will work to keep her personal preferences from influencing her counseling of the family.
In step 4, Dr R realizes that her role changes from guiding decisions to primarily supporting the family. In speaking with the family and creating a plan of care (step 5), she focuses on emotional counseling regarding the acceptance of imminent death rather than choosing biomedical interventions, and she assures the family members that treatments will be focused on palliation of symptoms. The family chooses to enroll Mr G in home hospice. Dr R continues to work closely with the family members to make certain that they do not feel abandoned.
LIMITATIONS OF THE TITRATING GUIDANCE MODEL
Our model has not been empirically tested and validated, although it is based on work by other authors about participation in medical decision making and about how communication regarding the process improves both satisfaction and outcomes. [27] [28] [29] Also, while our model could be used by an interdisciplinary team, we have not explicitly outlined this process. Future research will be needed to test and validate the proposed model.
In conclusion, as medicine advances, the possibilities it offers for sustaining life sometimes forces patients and their families to make choices that can seem difficult if not impossible. We have created a model for decision making that recognizes how a physician's role ought to change with the uncertainty of the desired outcome and the chance of restoring an acceptable quality of life. While the model was applied to 3 scenarios in this discussion, it could theoretically be applied to aid decision making for any illness in any case. By using the titrating guidance paradigm, these difficult decisions can be turned into ones that yield to medical expertise, good communication, and personal caring. were matched by propensity score to patients receiving usual care. Generalized linear models were estimated for costs per admission and per hospital day.
Results: Of the 2966 palliative care patients who were discharged alive, 2630 palliative care patients (89%) were matched to 18 427 usual care patients, and of the 2388 palliative care patients who died, 2278 (95%) were matched to 2124 usual care patients. The palliative care patients who were discharged alive had an adjusted net savings of $1696 in direct costs per admission (P=.004) and $279 in direct costs per day (PϽ.001) including significant reductions in laboratory and intensive care unit costs compared with usual care patients. The palliative care patients who died had an adjusted net savings of $4908 in direct costs per admission (P=.003) and $374 in direct costs per day (PϽ.001) including significant reductions in pharmacy, laboratory, and intensive care unit costs compared with usual care patients. Two confirmatory analyses were performed. Including mean costs per day before palliative care and before a comparable reference day for usual care patients in the propensity score models resulted in similar results. Estimating costs for palliative care patients assuming that they did not receive palliative care resulted in projected costs that were not significantly different from usual care costs.
Conclusion:
Hospital palliative care consultation teams are associated with significant hospital cost savings.
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A DVANCES IN DISEASE PREVENtion, disease-modifying therapies, and medical technology in combination with the aging of the population have resulted in a dramatic growth in the number of adults living with serious illness. 1 Despite enormous expenditures, patients with serious illness receive poor quality medical care, characterized by untreated symptoms, unmet personal care needs, high caregiver burden, and low patient and family satisfaction. 2 Palliative care is the interdisciplinary specialty that focuses on improving quality of life for patients with advanced illness and for their families through pain and symptom management, communication and support for medical decisions concordant with goals of care, and assurance of safe transitions between care settings. 3 Until a decade ago, palliative care in the United States was typically available only to patients living at home and enrolled in hospice. Now, palliative care programs targeting acutely ill patients are found increasingly in hospitals. As of 2005, 30% of US hospitals and 70% of hospitals with more than 250 beds reported the presence of a palliative care program-an increase of 96% from 2000. 4 Unlike hospice, hospital palliative care is provided simultaneously with all other appropriate disease-directed treatments. 3 Hospital palliative care programs have been shown to improve physical and psychological symptom management, caregiver well-being, and family satisfaction, 2,5-9 and small, single-site studies suggest that palliative care programs may reduce hospital and intensive care unit (ICU) expenditures by clarifying goals of care and assisting patients and families to select treatments that meet those goals. [10] [11] [12] [13] [14] [15] This study was undertaken to estimate the effect of palliative care consultation programs on hospital costs.
METHODS
We used hospital administrative data to compare hospital costs of patients receiving palliative care consultation matched by propensity score [16] [17] [18] with patients receiving usual care from 2002 through 2004.
SAMPLE
Eight geographically and structurally diverse hospitals representing low-, middle-, and high-cost markets served by 6 mature palliative care consultation teams (1 team served 3 hospitals) were included ( Table 1) . For the main analyses, the patient sample included all patients 18 years or older who had lengths of stay of 7 to 30 days. We excluded patients with short lengths of stay because these patients were unlikely to receive palliative care consultation. Patients with lengths of stay of more than 30 days were excluded because they represented outliers that were unlikely to be generalizable. Patients receiving palliative care were identified through the palliative care consultation teams' administrative databases and billing records. The initial sample included 43 973 patients discharged alive and 4726 patients who died in hospital.
PATIENT FACTORS
We used hospital databases to abstract patient characteristics. Medical comorbidities were determined using the Elixhauser algorithm that includes 30 categories of comorbid illnesses identified by secondary diagnosis codes and discharge diagnosisrelated groups.
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COSTS
Costs were abstracted from the hospitals' cost accounting systems. Each hospital used the same system, TSI (Transitions Systems Inc, Boston, Massachusetts). TSI tracks all hospital resources and assigns cost (not charge) values to these resources. These estimates are based on direct acquisition costs for supplies and time-and-motion studies for labor costs. 20 Various procedures are also used to determine the proportion of other costs, such as plant costs (eg, lighting and heating), that should be applied to each resource. This approach is generally considered the most accurate method to estimate costs. 20 We abstracted direct and total costs for each subject for each hospital day and for the entire admission. Direct costs are costs that can be directly attributable to medications, procedures, or services. Indirect costs are the general costs of running a hospital that are not directly related to the test or service. Total costs are the sum of direct and indirect costs. We used Uniform Billing 92 codes to aggregate direct costs into specific categories that included the following: ICU, pharmacy and intravenous therapy, laboratory, and diagnostic imaging costs. 21 All costs were converted into 2004 US dollars.
ANALYSES
Subjects were stratified by hospital site and then within each hospital into 2 strata comprising live discharges and hospital deaths. We computed propensity scores for each subject within each stratum. [16] [17] [18] 22 Propensity scores were determined by regressing whether patients received palliative care consultation on all patient characteristics present at hospital admission listed in the hospital databases. These variables included patient age, sex, marital status, medical insurance, primary diagnosis, attending physician specialty, and Elixhauser comorbidity score. Within each stratum we matched each patient receiving palliative care consultation with 1 or more usual care patients whose logit of their propensity score was within ±0.05 standard deviations of the logit of the palliative care patient's score. Unmatched patients were excluded, and all subsequent analyses included matched live discharges and matched hospital deaths.
Bivariate comparisons of unadjusted per diem costs and patient demographics were examined using unpaired t tests and 2 tests as appropriate. Usual care patients' data were weighted to account for the one-to-many propensity score matching algorithm. Generalized linear models (GLMs) using normalized weighted data were estimated for total and direct costs per hospital admission and hospital day. In addition, we estimated GLMs for pharmacy, diagnostic imaging, laboratory test, and ICU direct costs for all usual care patients admitted to an ICU and for WWW.ARCHINTERNMED.COM 1784 patients receiving palliative care consultation prior to ICU discharge. The GLMs were specified as having a gamma distribution and log link. 23, 24 The dependent variable was cost, and the independent variables included patient age, principal diagnosis, comorbidity score, palliative care team, attending physician specialty, marital status, insurance type, hospital discharge site for live discharges, and the key independent variable, whether the patient received palliative care consultation. Each cost model was adjusted for clustering by hospital. The GLM was used to examine the effects of palliative care consultation on hospital length of stay in days controlling for the aforementioned covariates.
ADDITIONAL CONFIRMATORY ANALYSES
We performed 2 additional confirmatory analyses. We matched usual care and palliative care patients by intensity of medical services before palliative care consultation to confirm that the palliative care and usual care groups were well matched. This analysis was performed by developing propensity scores using mean direct daily costs before consultation (palliative care patients) and before a corresponding reference day (usual care) as a regressor in the propensity score models. The reference day for usual care patients was hospital day 6 for patients with lengths of stay of 10 days or less, day 10 for those with lengths of stay of 11 to 20 days, and day 18 for those with lengths of stay longer than 20 days. These reference days represented the average day of consultation for palliative care patients for lengths of stay within these 3 categories. The GLMs were used to estimate costs for the usual care and palliative care patients.
We also used the GLM to model costs up to the day before consultation for palliative care patients. We then used these models to predict hypothetical costs in the absence of a palliative care consultation for the remaining length of stay, assuming that the slope of the cost curves remained constant, as was actually observed for usual care patients. We compared these predicted costs to actual costs for palliative care patients.
All analyses were performed with Stata version 9.2 statistical software (StataCorp, College Station, Texas), and this study was approved by the institutional review boards of all sites.
RESULTS
Of the 2966 patients who received palliative care consultation and who were discharged alive, 2630 (89%) were matched to 18 427 usual care patients discharged alive, and of the 2388 palliative care patients who died in hospital, 2278 (95%) were matched to 2124 usual care patients who died in hospital ( Table 2 and Table 3 ). There were no statistically significant differences in length of stay between usual care and palliative care patients discharged alive (12.4 vs 13.1 days; P = .12) and those who died in hospital (13.9 vs 14.1 days; P = .40).
COSTS FOR PATIENTS DISCHARGED ALIVE
Patients receiving palliative care consultation had significantly lower costs than usual care patients. For patients discharged alive, palliative care consultation was associated with adjusted net savings in total costs of $2642 per admission (P=.02) and $279 per day (PϽ.001) compared with usual care. Adjusted net savings in direct costs associated with palliative care were $1696 per admission (P=.004) and $174 per day (PϽ.001). These savings included significant reductions in laboratory costs ($424 per admission; P Ͻ .001) and ICU costs ($5178 per ICU admission; PϽ.001) ( Table 4) . Including outlier patients-those with lengths of stay less than 7 days and longer than 30 daysresulted in reductions in direct costs per day of $275 and $246, respectively, favoring palliative care.
COSTS FOR PATIENTS WHO DIED IN HOSPITAL
For patients who died in hospital, palliative care consultation was associated with adjusted net savings in total costs of $6896 per admission (P=.001) and $549 per day (PϽ.001). Adjusted net savings in direct costs were $4908 per admission (P = .003) and $374 per day (P Ͻ .001). These reductions in direct costs included significant reductions in pharmacy costs ($1544 per admission; P=.04), laboratory tests ($926 per admission; PϽ.001), and ICU costs ($6613 per ICU admission; PϽ.001) ( Table 4 ). Including outlier patients-those with lengths of stay less than 7 days and longer than 30 days-resulted in reductions in direct costs per day of $559 and $370, respectively, favoring palliative care.
CONFIRMATORY ANALYSES
Including mean cost per day before palliative care consultation and before the reference day for usual care subjects in the propensity score models as a surrogate for intensity of medical services resulted in qualitatively similar results (ie, the parameter estimates were contained within the 95% confidence intervals of the estimates of the primary analyses) across all major cost categories albeit with fewer matched subjects (78% of palliative care patients discharged alive could be matched to a usual care patient and 92% of palliative care patients who died could be matched to a usual care patient). Figure 1 displays mean daily direct costs for live discharges and hospital deaths. For palliative care patients, we plotted the 6 days before and after palliative care consultation (day 0). For usual care patients, day 0 was the reference day established for the confirmatory analyses previously described. There were no significant differences observed between the cost curves' slopes or the mean daily direct costs for palliative care and matched usual care groups before the day of consultation (palliative care patients) or the reference day (usual care patients). Whereas the slope of the usual care cost curve approached zero following the reference day, palliative care consultation was associated with a significant reduction in hospital costs 24 to 48 hours after consultation. For patients discharged alive ( Figure 1A ), mean direct costs per day decreased from $843 for the 48 hours before palliative care consultation to $605 for the 48 hours after consultation (P=.001) and from $1163 for the 48 hours before consultation to $589 for the 48 hours after consultation (P=.003) for patients who died ( Figure 1B) .
We projected what the adjusted direct costs per admission for palliative care patients would have been if they had not received palliative care consultation. Projected direct costs per admission were $11 787 for patients discharged alive and $22 301 for patients who died in hospital. These projected costs were not significantly different from the costs actually observed in the usual care group ($11 140 [P = .26] for live discharges and $22 674 [P=.44] for deceased patients).
Finally, to explore the question of whether the recommendations of the palliative care consultation teams reduced hospital costs or were simply a marker of changes in treatment plans already implemented by the primary care team, we plotted mean direct costs for each day of admission for usual care patients and for patients receiving palliative care consultation on hospital days 7, 10, and 15 for patients who died (Figure 2) . Costs for patients who received palliative care were no different from those in the usual care group until 24 to 48 hours after palliative care consultation at which time costs in the palliative care group started to decrease. A similar pattern was observed for patients discharged alive (data not shown).
COMMENT
Studies have consistently demonstrated that patients with life-threatening illness experience untreated pain and other symptoms; lengthy hospitalizations involving unwanted, often low-yield and costly medical treatments; and low overall family satisfaction. 2, 9, [25] [26] [27] Hospital palliative care consultation programs have been associated with reductions in symptoms and higher family satisfaction with overall care, and greater emotional support as compared with usual care. 2, 6, 28, 29 Although others have postulated that palliative care programs could substantially reduce hospital costs, 26, 30 this study is the first, to our knowledge, to empirically evaluate the actual effect of palliative care on US hospi- tal costs using a sample size sufficient to assure reliable results, using propensity score-matched control patients and enrolling patients from 8 diverse hospitals serving low-, medium-, and high-cost markets, thus enhancing the generalizability of our results. Our finding that palliative care consultation is associated with significant reductions in hospital costs has important implications for hospitals and policy makers.
OTHER FACTORS THAT COULD ACCOUNT FOR THE OBSERVED SAVINGS
It is possible that the cost saving observed might have occurred spontaneously without the palliative care consultation team's intervention due to unmeasured confounding variables that we were unable to obtain from administrative data. Specifically, it is possible that before the palliative care consultation, physicians recommended and patients agreed to forego some therapies and that the palliative care team enacted a previously decided-on care plan. Data suggest that this is unlikely. Although this study was a retrospective analysis, 3 of the participating palliative care teams have reported that most palliative care consultations are requested to help address goals of care and to discuss with patients all treatment options, including that of foregoing treatments that will not meet their goals or prolong life in a meaningful fashion. 12, 31, 32 Other studies lend credence to this argument. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT), which included more than 9000 seriously ill adults, demonstrated that patient preferences and physicians' knowledge of patients' preferences and prognoses did not have a measurable effect on hospital costs and treatments. 25 Our data suggest that it was the actions of the palliative care teams that resulted in cost reductions. First, we found no significant differences in the palliative care and usual care groups across all observable patient characteristics, suggesting that the 2 groups were well matched. Second, as shown in Figure 1 and Figure 2 , the decrease in costs consistently occurred 48 hours after consultation-no matter when the consultation occurred-and no corresponding decline was observed in the usual care group at any point in their hospital stay. If palliative care was only a marker for change, we would have expected the cost curves to drop before or at the time of consultation rather than be delayed for 48 hours, as was observed. Finally, our confirmatory analyses replicated our main findings. Specifically, including mean cost per day before palliative care consultation or the equivalent reference day for usual care patients as a surrogate for intensity of medical services in the propensity score analyses resulted in almost identical results. A comparison of the actual costs for palliative care patients after palliative care consultation with estimated costs in the case that palliative care consultation had hypothetically not occurred also resulted in almost identical savings.
WHAT ACCOUNTS FOR THE COST SAVINGS?
While it may appear self-evident that discontinuing costly nonbeneficial interventions among seriously ill patients reduces hospital costs, such a fundamental shift in the usual hospital care pathway is neither a simple nor straightforward process, given the highly patterned treatment culture of the UShospital,whichisstructuredtoprolonglifeandavertdeath at all costs. In this context, the fact that palliative care consultation appeared to consistently influence this process is an important finding. Indeed, prior studies have definitively demonstrated that even when seriously ill patients' preferences for treatments focused solely on comfort are documented and known by their physicians, these patients continue to receive low-yield, burdensome, and high-cost tests and treatments including prolonged ICU stays-a probable result of highly ingrained physician and hospital practice patterns and prevailing hospital culture. 25 Our data suggest that palliative care consultation fundamentally shifts the course of care off the usual hospital pathway and in doing so, sig- The solid line represents the regression curve of actual costs before palliative care consultation (day 0) and estimated costs (days 1-6) assuming that palliative care consultation had not occurred. The dashed line represents direct costs per day for usual care patients for the 6 days before and after hospital day 6 (patients with lengths of stay of Յ10 days), hospital day 10 (for patients with lengths of stay of 11-20 days), or hospital day 18 (for patients with lengths of stay of Ͼ20 days). nificantly reduces costs. This shift is likely accomplished by establishing clear treatment goals, reviewing current treatments to establish their concordance with these goals, and recommendingandlegitimizingdiscontinuationoftreatments or tests that do not meet established goals.
RELATIONSHIP TO OTHER STUDIES
Our data confirm and extend previously published small single-site studies. Two studies performed at Department of Veterans Affairs (VA) medical centers reported reduced health care utilization and costs associated with palliative care programs. 10, 11 Outside the VA, Cowan 33 reported reduced charges associated with a palliative care consultation team in a community hospital; Elsayem and colleagues 13 reported reduced charges associated with a palliative care inpatient unit in a cancer hospital; and Campbell and Frank 34 and Norton and colleagues 14 demonstrated reductions in ICU resource utilization associated with an ICU-based palliative care team. Two single site studies have looked at non-VA overall hospital costs. Smith and colleagues 12 found significantly lower costs for patients who died in an inpatient palliative care unit compared with matched controls who died in other hospital units, and Ciemens and colleagues 15 observed similar findings associated with a palliative care consultation service.
Our study has several strengths compared with these studies. We included data from 8 geographically and structurally diverse hospitals but with similarly structured palliative care consultation teams-now the standard of palliative care practice in US hospitals-thus enhancing the generalizability of our results. Prior studies used highly variable models of care and interventions that are neither comparable nor replicable. We used hospital costs rather than charges and thus our results reflect true rather than estimated savings. Finally, our estimates of savings per day may be conservative because the main analyses did not include patients with a length of stay longer than 30 days. The inclusion of outliers resulted in even greater savings.
IMPLICATIONS
Our results provide strong fiscal incentives for hospitals and policy makers to develop or expand palliative care consultation programs-programs that have already been demonstrated to improve quality and patient and family satisfaction. The most medically complex patients, such as the patients enrolled in this study, account for a growing proportionofadmissions,beddays,anduseofhospitalresources. The median operating margin for a hospital is 2% ($27-$40 per day), 35 thus the $174-per-day savings in direct costs for live discharges associated with palliative care consultation in this study could have a significant impact on hospital performance, particularly as the proportion of older, complex, and chronically ill admissions increases over the coming years. Whether a hospital is paid on a diagnosis-related group or a per diem basis, they benefit from the lower costs. As the proportion of discounted fee for service patients continues to dwindle, this is of increasing importance. 36 Hospital palliative care programs are also likely to help reduce Medicare expenditures. Five percent of Medicare enrollees with the most serious illness account for over 43% of Medicare expenditures, with the top 25% of enrollees accounting for 85% of the costs. 37 Threequarters of these 25% of "highest cost" enrollees have at least 1 hospital admission per year, and approximately 60% of total Medicare health care expenditures are for hospital care. 37, 38 Expansion of palliative care consultation programs to adequately serve the complex patient base of hospitals reduces cost pressures between hospitals and Medicare. Discharge orders and care plans resulting from palliative care consultations may also reduce ongoing care costs in the outpatient arena.
LIMITATIONS
This was not a randomized trial, and it is possible that the cost differences resulted from unmeasured differences between the 2 groups. We used several design and analytic measures to limit bias and confounding. First, we included subjects with a defined length of stay to eliminate the effects of outliers. Second, we stratified our sample both by site and by vital status prior to propensity score matching to minimize unobserved confounders. Third, we used propensity score methods to match patients based on patient characteristics to balance observed covariates and cannot draw conclusions about unmatched patients. However, the numbers of unmatched palliative care patients were relatively small (11% of patients discharged alive and 5% of patients who died). Finally, we used appropriate multivariable techniques to control for non-patient-based characteristics. Thus, although possible, we believe that it is unlikely that the magnitude of the effects noted here could be due to persistent unobserved confounders such as patient or physician preferences. Specifically, if patient preferences or another unmeasured variable were confounding our results, the parameter estimate would need to be several orders of magnitude larger than that observed in SUPPORT for us to have obtained these results, given the effects sizes observed in our models. 25 
CONCLUSIONS
This study found that palliative care consultation was associated with a reduction in direct hospital costs of almost $1700 per admission ($174 per day) for live discharges and of almost $5000 per admission ($374 per day) for patients who died. For an average 400-bed hospital containing an interdisciplinary palliative care team seeing 500 patients a year (300 live discharges and 200 hospital deaths), these figures translate into a net savings of $1.3 million per year after adding physician revenues ($240 000) and subtracting personnel costs ($418 000). 39 This study adds to the growing literature on the benefits of palliative care consultation by demonstrating that in addition to improved clinical care and patient, family, and physician satisfaction, these programs are associated with considerable reductions in hospital costs. The growth of the number of adults living with advanced and complex chronic illnesses, the documented inadequacies in care quality, and the increases in expenditures highlight the need for efficient models such as palliative care consultation teams that deliver quality services to complex patient populations.
(REPRINTED) ARCH INTERN MED/ VOL 168 (NO. 16), SEP 8, 2008 WWW.ARCHINTERNMED.COM 1789 persistent jerking that can be painful and significantly impair quality of life. 31 It is believed to lie on a spectrum of neuroexcitatory toxicities of opioids including akathisia, hyperalgesia, and seizures, although it can present as an isolated symptom. 24 A recent study that prospectively evaluated cancer patients taking morphine for dose-limiting toxicities found that 3.5% reported any myoclonus and <1% reported moderate or severe symptoms. 27 ORM's incidence with other opioids is unknown.
Pathophysiology
Multiple pathophysiologic mechanisms have been proposed to explain ORM, mostly implicating the neuroexcitatory effects of opioid metabolites such as the 3-glucuronides of morphine and hydromorphone. A disinhibitory spinal antiglycinergic effect of these metabolites, as well as activation of the NMDA receptor, have both been proposed. 20, 32 Per this model, patients receiving long-term, high-dose opioids with neurotoxic metabolites such as morphine and hydromorphone are most likely to accumulate sufficient metabolites within the CNS to develop ORM. Patients with renal insufficiency should be particularly at risk, given that the 3-glucuronides are renally excreted. Along these lines, fentanyl and methadone have been proposed as opioids less likely to cause ORM, as they lack active metabolites. Methadone has been particularly recommended because it also directly antagonizes the NMDA receptor. 32 At best, however, this model is incomplete and is belied by the following observations. First, both fentanyl and methadone cause myoclonus and hyperalgesia. 2, 23, 31 Second, myoclonus has been reported with low-dose opioids 19, 24 and with short-term dosing. 24 Third, renal insufficiency has not been a prominent comorbidity in the case reporting of ORM. It is possible that myoclonus results from different mechanisms in different patients and with different opioids and that the ''neurotoxic metabolite'' hypothesis explains most but not all myoclonus that is encountered clinically. Until ORM is studied systematically, the contribution of various risk factors, such as opioid type, dose, duration of therapy, and patient characteristics, will not be clear.
Treatment of ORM
ORM should be suspected in any patient receiving an opioid who has myoclonus, although typically the diagnosis is confirmed only after the myoclonus resolves with cessation of the offending drug. Attention should be given to other causes of myoclonus including electrolyte disturbances, b-lactam antibiotics, and both tricyclic and newer antidepressants. 6 Mild myoclonus can be watched without intervention. 20 Benzodiazepine therapy and opioid dose reduction/rotation are the most common strategies used for moderate to severe myoclonus. Benzodiazepines nonspecifically suppress myoclonus from a variety of causes and are particularly helpful for mild to moderate symptoms. 20 Dantrolene and baclofen are other suppressive agents that have been reported to be successful. 19, 20 Severe myoclonus, not responsive to opioid dose reduction or rotation, may require sedating doses of benzodiazepines. This may be acceptable for moribund patients but creates a therapeutic conundrum for healthier patients. A multidisciplinary approach, using the full complement of nonopioid analgesic modalities, is the best strategy.
Besides pharmacological suppressive therapy, reducing exposure to the offending opioid, either by dose reduction or rotation to another opioid, is often attempted. Opioid rotation is a well-accepted approach for any patient with inadequate analgesia or dose-limiting opioid toxicities. 21 It has been studied both retrospectively and prospectively and has been reported to be successful overall 50% to 80% of the time; however, rates of success specifically for myoclonus have not been reported. 27 If rotation is successful, the myoclonus usually attenuates within 48 hours. 2, 20 In this case of far advanced cancer, myoclonus developed after the patient was given high-dose hydromorphone, improving only briefly with dose reduction and the addition of methadone and clonazepam. An alternative initial strategy would have been to completely discontinue the hydromorphone, as continuing even reduced doses of hydromorphone may have been sufficient to perpetuate the myoclonus and instead use intravenous fentanyl or methadone as the sole opioid. In our experience, some cases can be resolved with this approach while maintaining normal mentation. However, in other cases, when trying to balance the risks and benefits of further opioid drug/dose manipulations against the degree of current and expected future patient suffering, and a very limited prognosis, the decision to provide sedation is very appropriate. Cases such as this require the full involvement from interdisciplinary pain and palliative care professionals.
Drew When performed in accordance with clinical practice guidelines, 10, 22 there is general consensus that palliative sedation (PS) is an ethical treatment intervention for patients at the end of life. Key to this determination are specific definitions and an ethical framework for decision-making.
Definitions
Palliative sedation is defined as ''the use of sedative medications, at least in part, to reduce patient awareness of distressing and intractable symptoms that are insufficiently controlled by symptom-specific therapies.'' 7 A refractory symptom is one for which all possible treatments have failed, or it is estimated that no methods are available for palliation within the time frame and risk-benefit ratio that the patient can tolerate. Given the subjective nature of intolerable suffering expressed by the patient, most clinical practice guidelines recommend that the determination of refractoriness be made after skilled multidisciplinary management by a palliative care specialist. 8, 10 An Ethical Framework PS is an ethically and legally well-accepted intervention. 25, 28 Typically limited to terminally ill patients with a prognosis of hours to days, the intention of PS is provision of patient comfort, consistent with the cardinal doctrine of beneficence. Because the desired outcome of comfort is contingent on lowering of patient consciousness, the principle of double effect is integral to PS. Namely, the ''good'' intention, symptom palliation, may result in the ''bad,'' or unintended, consequence of earlier death. The principle of proportionality argues that the choice for PS should be proportionate to the degree of patient distress, available treatment options, expected benefits, and expected harms. 22 Another guiding principle is that of patient autonomy; as for other treatment interventions, informed consent is required. If the patient lacks decision-making capacity, a surrogate should participate in the decision-making process with the interdisciplinary medical team. 10, 22 Symptoms Requiring PS For this patient, refractory myoclonus is 1 of many symptoms that may be treated with PS at the end of life. However, the most common indication for PS is agitated delirium. Other common indications include dyspnea, bleeding, seizure, and pain.
12 Symptom-specific interventions should always be attempted first; only for refractory symptoms is PS a treatment option. For this patient, attempted interventions included opioid rotation, hydration, treatment of infection, and addition of benzodiazepines, all without durable benefit. This patient was clearly at the end of her life, and controlling her symptoms was of utmost importance to the patient and her family. Despite labeling myoclonus as refractory, initiating PS should not prevent her clinician from reevaluating its need, with downward titration of midazolam, should her symptoms improve.
Drug Therapy
When establishing PS, midazolam is the drug of choice due to its rapid onset of action, short half-life, dose-dependent sedative effect, and an available antidote, flumazenil. 17 The American Academy of Hospice and Palliative Medicine (AAHPM) differentiates 2 types of PS, based on the level of consciousness preserved. 1 In the milder form, alertness is preserved to some degree and communication may be possible. If ineffective, a deeper degree of sedation to unconsciousness is induced. The doses of midazolam used in this patient, 0.5 mg/h and 5 mg/h, are consistent with this approach. The degree of sedation, mild versus deep, is proportionate to the level of the patient's distress; thus, the principle of proportionality, with the intention of sedation to palliate suffering, rather than hastening death, holds true. 10 In many US hospitals, midazolam use is restricted to intensive care units or as conscious sedation, limiting applicability for PS. These policies may be very restrictive, leading providers away from using midazolam and from following recommended clinical practice guidelines developed to support the ethical conduct of effective PS. Palliative care providers in these hospitals are required to establish policies for the use PS.
